Q-omics provides the consensus-scored ST14 profile across patient tissues and cancer cell-line models. ST14 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ST14 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ST14 RNA expression shows 17,383 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where ST14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST14 survival associations across molecular data types. ST14 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST14 RNA expression–survival associations across cancer types. High ST14 expression shows unfavorable associations in BRCA, UVM, ACC and LGG, but favorable associations in KIRP and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ST14 RNA expression.
This table summarizes ST14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ST14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST14 shows lower tumor expression in KIRC and higher tumor expression in THCA, LUAD, BLCA, LUSC and UCEC. The KIRC box plot shows higher ST14 RNA expression in normal versus tumor tissue (log2 FC = −2.244, t-test p < 0.001).
This table shows molecular features associated with ST14 in patient tissues and cancer cell lines. In patient samples, ST14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ST14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
